Yondelis Ova UK . NICE declined to recommend PharmaMar's Yondelis (trabectedin), as well as the generics gemcitabine and topetecan, as treatments for ovarian cancer that has returned for the first time six months or more after platinum-based chemotherapy.

NICE to update ovarian cancer drug guidelines .

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin .

The news is less positive for PharmaMar, which already has a NICE recommendation for the use of Yondelis for the treatment of advanced soft tissue sarcoma.

The draft guidance is now in consultation stage and open to comments until October 18, 2013.

...